Intercept Pharmaceuticals has accused the FDA of moving the goalposts during its review of a potential blockbuster drug for the fatty liver disease known as NASH following a rejection. Intercept’s CEO ...
Stories by Iftikhar A. Khan Iftikhar A. Khan is an Islamabad-based reporter for Dawn with over three decades of experience in journalism. He covers the parliament, the Election Commission of Pakistan, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback